Alfresa's net sales FY 2013-2022
In the fiscal year 2022 ending in March, Alfresa Holdings Corporation recorded net sales of approximately 2.59 trillion Japanese yen, down from almost 2.61 trillion yen in the previous fiscal year.
The main businesses of the Japanese pharmaceutical company include ethical pharmaceutical wholesaling, self-medication products wholesaling, manufacturing, and medical-related business.
The main businesses of the Japanese pharmaceutical company include ethical pharmaceutical wholesaling, self-medication products wholesaling, manufacturing, and medical-related business.
